Neurocrine Is Making a $2.9 Billion Bet on a New Kind of Drug
The company is acquiring Soleno Therapeutics to add a newly approved Prader‑Willi syndrome treatment to its portfolio.
Source: www.inc.com
The company is acquiring Soleno Therapeutics to add a newly approved Prader‑Willi syndrome treatment to its portfolio.